Abstract 276P
Background
Metastatic hormone sensitive prostate cancer (mHSPC) is now in abundance of treatment options. In this heterogenous group, appropriate biomarkers to choose treatment decisions are unavailable. The present study aimed to assess the prognostic significance of p53 in metastatic prostate cancer patients.
Methods
Patients ≥18 yrs of age, newly diagnosed high volume (CHAARTED criteria) mHSPC, adenocarcinoma histology & gleason score ≥8 were considered for the study. Those with known/suspected cancer susceptibility were excluded. Aim of the study was to assess the p53 status in Indian mHSPC patients, time to castration resistance and overall survival stratified as per p53 status. Eligible patients received androgen deprivation therapy and docetaxel 75mg/m2 q3weekly for 6 cycles. Immunohistochemistry for p53 was done on the prostate biopsy blocks and ≥20% nuclear immunoreactivity was considered as positive. Genomic DNA isolated from the tissue blocks was analysed for mutations in p53 exon 5 to 8 by PCR and confirmed by Sanger sequencing. At progression to CRPC, patients received therapy as per standard guidelines. The study started in 2019 after approval by the Institutional Ethics Committee.
Results
Out of 75 enrolled patients, 50 patients are eligible for present analysis. Among 50 high volume mHSPC patients, p53 was positive in 17 (34%) patients. In the overall population, progression to CRPC was seen in 26 (52%) patients at last follow up. Median follow up was 22 months. Time to CRPC in p53+ve vs. p53-ve patients was 16.6% and 37.6% (p-0.326). The 2yr OS was 51.9% vs 85.8% (p53+ve vs p53-ve respectively, p-0.041). Out of 11 samples tested, 6 (55%) mutations were found: p53 exon 8 (c.280AGA>AAA, c.287GAG>AAA, c. 279-280 GGGAGA ins GGGAAGA, c.280-281AGA>AAG) and exon 7 (c.249CGG>CGA, c.231-233 ACCACCATCCAC ins ACCACCAATCCACC). Remaining data on mutation status is being analysed.
Conclusions
This analysis shows the poor OS among p53+ve metastatic prostate cancer patients in Indian population. However, their progression after 1st-line docetaxel chemotherapy was not statistically significant. Llimitation of the study is small sample size. Differential response of p53mutant patients to other approved treatment options in this disease needs to be explored.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Indian Co-operative Oncology Network (ICON).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract